As shown in Figure 5B, three mutations, including the MYO18A mutation in the founding clone and FBXW7 and the ATM mutation in the dominant subclone, could be used to stratify these 78 CRC patients into four subgroups that had different clinical outcomes. The gene discussed is ATM; the disease is colorectal carcinoma.